As imaging studios have markedly increased in the past two decades, so has the concern among some clinicians and media surrounding radiation dose management.

Irving L. Weissman, MD’s stem cell research using PET and optical imaging has revealed how a novel antibody-based biomarker highlights areas of residual cancer with broad potential for therapeutic use.

Molecular imaging is beginning to give cardiologists insight into biological processes behind heart failure, knowledge that may allow them to monitor disease progression and tailor therapies. But market realities still pose barriers.

“Alzheimer’s disease is probably the most underfunded disease in the U.S.,” charges Dean M. Hartley, PhD, director of science initiatives, medical and scientific relations, for the Alzheimer’s Association.

An exploration of recent projects at Argonne National Laboratory and Johns Hopkins University traverse the numerical and graphical landscape of cerebral blood flow, the pathology of malaria, brain aneurysm, sickle cell anemia and even cancer.

The past year has been a groundbreaking one for neurology. 

When I began my PhD research almost 40 years ago, nuclear medicine research was almost entirely focused on diagnosis. 

Advanced Accelerator Applications (AAA), a major molecular medicine company based in Bourg en Bresse, France, announced Mar. 4 that the firm had acquired 100 percent of shares of the privately held U.K.-based Imaging Equipment, a distributor of nuclear medicine technologies and radiopharmaceuticals across the U.K. and Ireland.